[1] [1] SCHADENDORF D, VAN AKKOOI A C J, BERKING C, et al. Melanoma ［J］. Lancet, 2018, 392(10151): 971-984.

[2] [2] FECHER L A, CUMMINGS S D, KEEFE M J, et al. Toward a molecular classification of melanoma ［J］. Journal of Clinical Oncology, 2007, 25(12): 1606-1620.

[3] [3] BEN-PORATH I, KOZAK C A, BENVENISTY N. Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22 ［J］. Genomics, 1998, 49(3): 443-447.

[4] [4] WANG Y W, CHENG H L, DING Y R, et al. EMP1, EMP2, and EMP3 as novel therapeutic targets in human cancer ［J］. Biochimica et Biophysica Acta-reviews on Cancer, 2017, 1868(1): 199-211.

[5] [5] CHRISTIANS A, POISEL E, HARTMANN C, et al. Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation ［J］. International Journal of Cancer, 2019, 145(2): 461-473.

[6] [6] HSIEH Y H, HSIEH S C, LEE C H, et al. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway ［J］. Oncotarget, 2015, 6(33): 34859-34874.

[7] [7] MA Q, ZHANG Y, LIANG H, et al. EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway ［J］. Cancer Letters, 2018, 430(1): 97-108.

[8] [8] ALAMINOS M, DAVALOS V, ROPERO S, et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma ［J］. Cancer Research, 2005, 65(7): 2565-2571.

[9] [9] FUMOTO S, HIYAMA K, TANIMOTO K, et al. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma ［J］. Cancer Letters, 2009, 274(1): 25-32.

[10] [10] HONG X C, FEN Y J, YAN G C, et al. Epithelial membrane protein 3 functions as an oncogene and is regulated by microRNA-765 in primary breast carcinoma ［J］. Molecular Medicine Reports, 2015, 12(5): 6445-6450.

[11] [11] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses ［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[12] [12] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses ［J］. Neoplasia, 2017, 19(8): 649-658.

[13] [13] LI T, FU J, ZENG Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells ［J］. Nucleic Acids Research, 2020, 48(W1): W509-W514.

[14] [14] JUN F, HONG J, LIU Q, et al. Epithelial membrane protein 3 regulates TGF-beta signaling activation in CD44-high glioblastoma ［J］. Oncotarget, 2017, 8(9): 14343-14358.

[15] [15] WANG X, XIONG H, LIANG D, et al. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients ［J］. BMC Cancer, 2020, 20(1): 378-378.

[16] [16] DUNN G P, BRUCE A T, IKEDA H, et al. Cancer immunoediting: from immunosurveillance to tumor escape ［J］. Nature Reviews Immunology, 2002, 3(11): 991-998.

[17] [17] GARRIDO F, CABRERA T, APTSIAURI N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy ［J］. International Journal of Cancer, 2010, 127(2): 249-256.

[18] [18] FRUCI D, BENEVOLO M, CIFALDI L, et al. Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time ［J］. Current Oncology Reports, 2012, 19(1): 39-41.

[19] [19] BENOIT M, DESNUES B, MEGE J L. Macrophage polarization in bacterial infections ［J］. Journal of Immunology, 2008, 181(6): 3733-3739.

[20] [20] SCHMIEDER A, MICHEL J, SCHONHAAR K, et al. Differentiation and gene expression profile of tumor-associated macrophages ［J］. Seminars in Cancer Biology, 2012, 22(4): 289-297.

[21] [21] WATKINS S K, EGILMEZ N K, SUTTLES J, et al. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo ［J］. Journal of Immunology, 2007, 178(3): 1357-1362.